Aspen’s pot of gold

    Aspen’s latest divestment brings its sales tally to R30bn in 18 months, bringing its debt under control and putting the group on a surer footing for growth — management says. Africa’s largest drug company, the JSE-listed Aspen, has sold the rights for its European thrombosis business to US pharmaceutical firm Mylan for R12.6-billion. It has, however, retained its thrombosis business in its core emerging markets including South-East Asia and sub-Saharan Africa. This is likely the last of the major disposals intended to refocus the business and cut debt.…

Read More